Cargando…

EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA

Ependymoma is the third most common malignant brain tumor in children. However, there is no effective chemotherapy identified and treatment is limited to surgery with or without adjuvant radiation therapy currently. Thus, to develop targeted therapy based on the underlying biology is an urgent need....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jacqueline Jufen, Jillette, Nathaniel, Li, Xiao-Nan, Cheng, Albert, Lau, Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715536/
http://dx.doi.org/10.1093/neuonc/noaa222.186
_version_ 1783618978385494016
author Zhu, Jacqueline Jufen
Jillette, Nathaniel
Li, Xiao-Nan
Cheng, Albert
Lau, Ching
author_facet Zhu, Jacqueline Jufen
Jillette, Nathaniel
Li, Xiao-Nan
Cheng, Albert
Lau, Ching
author_sort Zhu, Jacqueline Jufen
collection PubMed
description Ependymoma is the third most common malignant brain tumor in children. However, there is no effective chemotherapy identified and treatment is limited to surgery with or without adjuvant radiation therapy currently. Thus, to develop targeted therapy based on the underlying biology is an urgent need. Since 2014, C11orf95-RELA fusion was found to be the most recurrent structural variation in approximately 70% of supratentorial ependymomas (ST-EPN), but the molecular mechanisms of oncogenesis are unclear. Here we utilized HEK293T transgene models and a ST-EPN cell line to investigate the epigenomic changes and transcriptional regulations by C11orf95-RELA fusion. By applying ChIP-seq and HiChIP approaches, we found C11orf95-RELA is a novel transcription factor that recognizes a specific DNA motif dictated by the C11orf95 component while the RELA component is required for driving the expression of ependymoma-associated genes such as CCND1 and L1CAM. Moreover, C11orf95-RELA modulates chromatin states and mediates chromatin interactions, leading to transcriptional reprogramming in ST-EPN cells. Multiple signaling pathways such as Notch signaling and G-protein signaling are identified to be involved in ST-EPN development. Our findings provide important characterization of the molecular underpinning of C11orf95-RELA fusion and shed light on potential therapeutic targets for C11orf95-RELA subtype ependymoma.
format Online
Article
Text
id pubmed-7715536
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77155362020-12-09 EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA Zhu, Jacqueline Jufen Jillette, Nathaniel Li, Xiao-Nan Cheng, Albert Lau, Ching Neuro Oncol Ependymoma Ependymoma is the third most common malignant brain tumor in children. However, there is no effective chemotherapy identified and treatment is limited to surgery with or without adjuvant radiation therapy currently. Thus, to develop targeted therapy based on the underlying biology is an urgent need. Since 2014, C11orf95-RELA fusion was found to be the most recurrent structural variation in approximately 70% of supratentorial ependymomas (ST-EPN), but the molecular mechanisms of oncogenesis are unclear. Here we utilized HEK293T transgene models and a ST-EPN cell line to investigate the epigenomic changes and transcriptional regulations by C11orf95-RELA fusion. By applying ChIP-seq and HiChIP approaches, we found C11orf95-RELA is a novel transcription factor that recognizes a specific DNA motif dictated by the C11orf95 component while the RELA component is required for driving the expression of ependymoma-associated genes such as CCND1 and L1CAM. Moreover, C11orf95-RELA modulates chromatin states and mediates chromatin interactions, leading to transcriptional reprogramming in ST-EPN cells. Multiple signaling pathways such as Notch signaling and G-protein signaling are identified to be involved in ST-EPN development. Our findings provide important characterization of the molecular underpinning of C11orf95-RELA fusion and shed light on potential therapeutic targets for C11orf95-RELA subtype ependymoma. Oxford University Press 2020-12-04 /pmc/articles/PMC7715536/ http://dx.doi.org/10.1093/neuonc/noaa222.186 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Ependymoma
Zhu, Jacqueline Jufen
Jillette, Nathaniel
Li, Xiao-Nan
Cheng, Albert
Lau, Ching
EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA
title EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA
title_full EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA
title_fullStr EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA
title_full_unstemmed EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA
title_short EPEN-53. C11orf95-RELA REPROGRAMS 3D EPIGENOME IN SUPRATENTORIAL EPENDYMOMA
title_sort epen-53. c11orf95-rela reprograms 3d epigenome in supratentorial ependymoma
topic Ependymoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715536/
http://dx.doi.org/10.1093/neuonc/noaa222.186
work_keys_str_mv AT zhujacquelinejufen epen53c11orf95relareprograms3depigenomeinsupratentorialependymoma
AT jillettenathaniel epen53c11orf95relareprograms3depigenomeinsupratentorialependymoma
AT lixiaonan epen53c11orf95relareprograms3depigenomeinsupratentorialependymoma
AT chengalbert epen53c11orf95relareprograms3depigenomeinsupratentorialependymoma
AT lauching epen53c11orf95relareprograms3depigenomeinsupratentorialependymoma